Allogene's Cancer Treatment Trial Data Shows Significant Improvement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ALLO?
Source: stocktwits
- Trial Results: In the ALPHA3 trial, cancer DNA levels dropped by 97.7% in the Cema-Cel group, while rising by 26.6% in the observation group, indicating the therapy's potential as an effective option for high-risk patients post-initial treatment.
- Significant Disease-Free Status: Among the 24 treated patients, 58.3% in the Cema-Cel group had no detectable disease compared to only 16.7% in the observation group, demonstrating the therapy's efficacy in clearing minimal residual disease (MRD).
- Strong Market Reaction: Shares of Allogene Therapeutics surged over 50% on Monday, reaching their highest level in over two years, with TD Cowen labeling the data a “home run” and maintaining a ‘Buy’ rating, reflecting strong market confidence in the company's prospects.
- Optimistic Investor Sentiment: Retail traders on Stocktwits expressed extremely bullish sentiment, with predictions of the stock potentially climbing to $8 despite dilution risks, as the stock has gained over 196% year-to-date.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALLO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALLO
Wall Street analysts forecast ALLO stock price to rise
11 Analyst Rating
10 Buy
0 Hold
1 Sell
Strong Buy
Current: 2.720
Low
5.00
Averages
8.50
High
14.00
Current: 2.720
Low
5.00
Averages
8.50
High
14.00
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysts Predict 180% Upside for Allogene Therapeutics
- Analyst Optimism: As of April 8, 2026, 85% of analysts have issued 'Buy' ratings for Allogene Therapeutics (NASDAQ:ALLO), reflecting strong market confidence in its future performance, with a price target of $7.50 implying an upside of 186.26%.
- Price Target Increase: On March 13, 2026, Piper Sandler raised its price target for Allogene from $7 to $8 while maintaining an 'Overweight' rating, indicating investor focus on the upcoming interim analysis from the ALPHA3 study, which is expected to show a 25%-30% MRD clearance advantage for cema-cel.
- Strong Financial Position: By the end of 2025, Allogene had $258.3 million in cash and cash equivalents, extending its operational runway into Q1 2028, while guiding for $150 million in operating cash expenses in 2026, demonstrating solid financial management.
- Net Loss Overview: The company reported a net loss of $38.8 million ($0.17 per share) for Q4 2025, with a total annual net loss of $190.9 million ($0.87 per share), indicating significant losses but ongoing commitment to advancing its CAR-T cell therapy development.
See More
Allogene Therapeutics CAR-T Therapy Shows Promising Phase 2 Trial Results
- Significant Efficacy Improvement: In the pivotal phase 2 trial of the CAR-T therapy cema-cel, 58.3% of patients achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, indicating a 41.6% absolute difference that highlights the therapy's substantial clinical potential in treating large B-cell lymphoma.
- ctDNA Levels Decline: At the first MRD assessment (day 45), the cema-cel group experienced a median plasma ctDNA reduction of 97.7%, while the observation cohort saw a median increase of 26.6%, showcasing cema-cel's superior efficacy in tumor marker clearance.
- Trial Progression: The trial is expected to complete enrollment by the end of 2027, with an interim event-free survival analysis projected for mid-2027 and a primary analysis in mid-2028, indicating the company's strategic planning in advancing CAR-T therapies.
- Positive Market Reaction: Following the encouraging clinical data, Allogene Therapeutics' stock surged approximately 46% in Monday morning trading, reflecting investor confidence in the future market potential of its CAR-T therapy.
See More
Allogene's Cancer Treatment Trial Data Shows Significant Improvement
- Trial Results: In the ALPHA3 trial, cancer DNA levels dropped by 97.7% in the Cema-Cel group, while rising by 26.6% in the observation group, indicating the therapy's potential as an effective option for high-risk patients post-initial treatment.
- Significant Disease-Free Status: Among the 24 treated patients, 58.3% in the Cema-Cel group had no detectable disease compared to only 16.7% in the observation group, demonstrating the therapy's efficacy in clearing minimal residual disease (MRD).
- Strong Market Reaction: Shares of Allogene Therapeutics surged over 50% on Monday, reaching their highest level in over two years, with TD Cowen labeling the data a “home run” and maintaining a ‘Buy’ rating, reflecting strong market confidence in the company's prospects.
- Optimistic Investor Sentiment: Retail traders on Stocktwits expressed extremely bullish sentiment, with predictions of the stock potentially climbing to $8 despite dilution risks, as the stock has gained over 196% year-to-date.
See More
Cema-Cel Treatment Shows Significant Efficacy in LBCL Trial
- Significant Efficacy: In the ALPHA3 trial, 58.3% of patients in the Cema-Cel arm achieved minimal residual disease (MRD) negativity compared to 16.7% in the observation arm, representing a 41.6% absolute difference, indicating Cema-Cel's potential to transform treatment strategies for high-risk large B-cell lymphoma (LBCL).
- Rapid Response: Following Cema-Cel treatment, patients exhibited a median 97.7% reduction in plasma circulating tumor DNA (ctDNA) levels by Day 45, contrasting with a 26.6% median increase in the observation arm, suggesting Cema-Cel's capability to swiftly reduce tumor burden and potentially improve patient outcomes.
- Good Safety Profile: Cema-Cel treatment was well-tolerated with no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and most patients were managed entirely on an outpatient basis, highlighting its favorable safety and tolerability.
- Community Center Engagement: Approximately 33% of screening activities and Cema-Cel infusions occurred at community cancer centers, underscoring the feasibility of implementing this therapy in broader healthcare settings, which may facilitate the adoption of CAR T therapies and enable earlier interventions for patients.
See More
El Pollo Loco Surges After Strong Q4 Earnings Beat Estimates
- Strong Earnings Report: El Pollo Loco reported Q4 earnings of $0.25 per share, surpassing analyst expectations of $0.20, indicating robust profitability that boosts investor confidence.
- Sales Exceed Expectations: The company achieved quarterly sales of $123.515 million, exceeding the analyst consensus of $122.783 million, demonstrating sustained strong market demand that drives overall performance.
- Stock Rating Upgrade: Benchmark upgraded El Pollo Loco's stock from Hold to Buy, reflecting a positive outlook on the company's future growth potential, which may attract more investor interest.
- Significant Stock Price Increase: Following the earnings report, El Pollo Loco's stock surged 17.6% to $12.79, indicating a strong market reaction to its financial performance and further solidifying its competitive position in the fast-food industry.
See More
Allogene Therapeutics Q4 2025 Earnings Call Insights
- Clinical Milestones: CEO David Chang emphasized that 2026 will be a 'defining year' for Allogene Therapeutics, focusing on clinical progress for the ALPHA3 and ALLO-329 programs, with key data expected in April and June, which will enhance the company's market position in cell therapy.
- Financial Health: As of December 31, 2025, the company reported $258.3 million in cash and equivalents, with management guiding for operating cash expenses of approximately $150 million in 2026, extending the cash runway into Q1 2028, ensuring sufficient funding for critical clinical trials.
- R&D Expenditures: The fourth quarter saw R&D expenses of $28.6 million, including $2.5 million in noncash stock compensation, with a net loss of $38.8 million, indicating ongoing investment in clinical trials while reflecting financial pressures in a competitive market.
- Market Positioning: Management remains optimistic about the clinical data from ALPHA3 and ALLO-329, emphasizing the relationship between MRD clearance rates and clinical outcomes, with upcoming data releases aimed at validating their treatment approaches and enhancing competitive positioning in the market.
See More
Analysts Predict 180% Upside for Allogene Therapeutics
- Analyst Optimism: As of April 8, 2026, 85% of analysts have issued 'Buy' ratings for Allogene Therapeutics (NASDAQ:ALLO), reflecting strong market confidence in its future performance, with a price target of $7.50 implying an upside of 186.26%.
- Price Target Increase: On March 13, 2026, Piper Sandler raised its price target for Allogene from $7 to $8 while maintaining an 'Overweight' rating, indicating investor focus on the upcoming interim analysis from the ALPHA3 study, which is expected to show a 25%-30% MRD clearance advantage for cema-cel.
- Strong Financial Position: By the end of 2025, Allogene had $258.3 million in cash and cash equivalents, extending its operational runway into Q1 2028, while guiding for $150 million in operating cash expenses in 2026, demonstrating solid financial management.
- Net Loss Overview: The company reported a net loss of $38.8 million ($0.17 per share) for Q4 2025, with a total annual net loss of $190.9 million ($0.87 per share), indicating significant losses but ongoing commitment to advancing its CAR-T cell therapy development.
See More
Allogene Therapeutics CAR-T Therapy Shows Promising Phase 2 Trial Results
- Significant Efficacy Improvement: In the pivotal phase 2 trial of the CAR-T therapy cema-cel, 58.3% of patients achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, indicating a 41.6% absolute difference that highlights the therapy's substantial clinical potential in treating large B-cell lymphoma.
- ctDNA Levels Decline: At the first MRD assessment (day 45), the cema-cel group experienced a median plasma ctDNA reduction of 97.7%, while the observation cohort saw a median increase of 26.6%, showcasing cema-cel's superior efficacy in tumor marker clearance.
- Trial Progression: The trial is expected to complete enrollment by the end of 2027, with an interim event-free survival analysis projected for mid-2027 and a primary analysis in mid-2028, indicating the company's strategic planning in advancing CAR-T therapies.
- Positive Market Reaction: Following the encouraging clinical data, Allogene Therapeutics' stock surged approximately 46% in Monday morning trading, reflecting investor confidence in the future market potential of its CAR-T therapy.
See More
Allogene's Cancer Treatment Trial Data Shows Significant Improvement
- Trial Results: In the ALPHA3 trial, cancer DNA levels dropped by 97.7% in the Cema-Cel group, while rising by 26.6% in the observation group, indicating the therapy's potential as an effective option for high-risk patients post-initial treatment.
- Significant Disease-Free Status: Among the 24 treated patients, 58.3% in the Cema-Cel group had no detectable disease compared to only 16.7% in the observation group, demonstrating the therapy's efficacy in clearing minimal residual disease (MRD).
- Strong Market Reaction: Shares of Allogene Therapeutics surged over 50% on Monday, reaching their highest level in over two years, with TD Cowen labeling the data a “home run” and maintaining a ‘Buy’ rating, reflecting strong market confidence in the company's prospects.
- Optimistic Investor Sentiment: Retail traders on Stocktwits expressed extremely bullish sentiment, with predictions of the stock potentially climbing to $8 despite dilution risks, as the stock has gained over 196% year-to-date.
See More
Cema-Cel Treatment Shows Significant Efficacy in LBCL Trial
- Significant Efficacy: In the ALPHA3 trial, 58.3% of patients in the Cema-Cel arm achieved minimal residual disease (MRD) negativity compared to 16.7% in the observation arm, representing a 41.6% absolute difference, indicating Cema-Cel's potential to transform treatment strategies for high-risk large B-cell lymphoma (LBCL).
- Rapid Response: Following Cema-Cel treatment, patients exhibited a median 97.7% reduction in plasma circulating tumor DNA (ctDNA) levels by Day 45, contrasting with a 26.6% median increase in the observation arm, suggesting Cema-Cel's capability to swiftly reduce tumor burden and potentially improve patient outcomes.
- Good Safety Profile: Cema-Cel treatment was well-tolerated with no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and most patients were managed entirely on an outpatient basis, highlighting its favorable safety and tolerability.
- Community Center Engagement: Approximately 33% of screening activities and Cema-Cel infusions occurred at community cancer centers, underscoring the feasibility of implementing this therapy in broader healthcare settings, which may facilitate the adoption of CAR T therapies and enable earlier interventions for patients.
See More
El Pollo Loco Surges After Strong Q4 Earnings Beat Estimates
- Strong Earnings Report: El Pollo Loco reported Q4 earnings of $0.25 per share, surpassing analyst expectations of $0.20, indicating robust profitability that boosts investor confidence.
- Sales Exceed Expectations: The company achieved quarterly sales of $123.515 million, exceeding the analyst consensus of $122.783 million, demonstrating sustained strong market demand that drives overall performance.
- Stock Rating Upgrade: Benchmark upgraded El Pollo Loco's stock from Hold to Buy, reflecting a positive outlook on the company's future growth potential, which may attract more investor interest.
- Significant Stock Price Increase: Following the earnings report, El Pollo Loco's stock surged 17.6% to $12.79, indicating a strong market reaction to its financial performance and further solidifying its competitive position in the fast-food industry.
See More
Allogene Therapeutics Q4 2025 Earnings Call Insights
- Clinical Milestones: CEO David Chang emphasized that 2026 will be a 'defining year' for Allogene Therapeutics, focusing on clinical progress for the ALPHA3 and ALLO-329 programs, with key data expected in April and June, which will enhance the company's market position in cell therapy.
- Financial Health: As of December 31, 2025, the company reported $258.3 million in cash and equivalents, with management guiding for operating cash expenses of approximately $150 million in 2026, extending the cash runway into Q1 2028, ensuring sufficient funding for critical clinical trials.
- R&D Expenditures: The fourth quarter saw R&D expenses of $28.6 million, including $2.5 million in noncash stock compensation, with a net loss of $38.8 million, indicating ongoing investment in clinical trials while reflecting financial pressures in a competitive market.
- Market Positioning: Management remains optimistic about the clinical data from ALPHA3 and ALLO-329, emphasizing the relationship between MRD clearance rates and clinical outcomes, with upcoming data releases aimed at validating their treatment approaches and enhancing competitive positioning in the market.
See More
